Pfizer New Haven Clinical Research Unit, New Haven, CT, USA.
Clinical Research and Development, KS1, 1 Portland Street, Cambridge, MA, 02139, USA.
Drugs R D. 2020 Mar;20(1):23-37. doi: 10.1007/s40268-020-00293-5.
A fixed-dose combination (FDC) of ibuprofen and acetaminophen has been developed that provides greater analgesic efficacy than either agent alone at the same doses without increasing the risk for adverse events.
We report three clinical phase I studies designed to assess the pharmacokinetics (PK) of the FDC of ibuprofen/acetaminophen 250/500 mg (administered as two tablets of ibuprofen 125 mg/acetaminophen 250 mg) in comparison with its individual components administered alone or together, and to determine the effect of food on the PK of the FDC. Two studies in healthy adults aged 18-55 years used a crossover design in which subjects received a single dose of each treatment with a 2-day washout period between each. In the third study, the bioavailability of ibuprofen and acetaminophen from a single oral dose of the FDC was assessed in healthy adolescents aged 12-17 years, inclusive.
A total of 35 and 46 subjects were enrolled in the two adult studies, respectively, and 21 were enrolled in the adolescent study. Ibuprofen and acetaminophen in the FDC were bioequivalent to the monocomponents administered alone or together. With food, the maximum concentration (C) for ibuprofen and acetaminophen from the FDC was reduced by 36% and 37%, respectively, and time to C (i.e. t) was delayed. Overall drug exposure to ibuprofen or acetaminophen in the fed versus fasted states was similar. In adolescents, overall exposure to acetaminophen and ibuprofen was comparable with that in adults, with a slightly higher overall exposure to ibuprofen. Exposure to acetaminophen and ibuprofen in adolescents aged 12-14 years was slightly higher versus those aged 15-17 years. Adverse events were similar across all treatment groups.
The FDC of ibuprofen/acetaminophen 250/500 mg has a PK profile similar to its monocomponent constituents when administered separately or coadministered, indicating no drug-drug interactions and no formulation effects. Similar to previous findings for the individual components, the rates of absorption of ibuprofen and acetaminophen from the FDC were slightly delayed in the presence of food. Overall, adolescents had similar exposures to acetaminophen and ibuprofen as adults, while younger adolescents had slightly greater exposure than older adolescents, probably due to their smaller body size. The FDC was generally well tolerated.
已开发出一种布洛芬和对乙酰氨基酚的固定剂量组合(FDC),与单独使用相同剂量的两种药物相比,它具有更大的镇痛效果,而不会增加不良事件的风险。
我们报告了三项临床 I 期研究,旨在评估布洛芬/对乙酰氨基酚 FDC(250/500mg,给予两片布洛芬 125mg/对乙酰氨基酚 250mg)的药代动力学(PK)与单独或联合使用其单个成分相比,以及确定食物对 FDC PK 的影响。两项在 18-55 岁健康成年人中进行的研究采用交叉设计,其中受试者接受每种治疗方法的单次剂量,每种剂量之间有 2 天的洗脱期。在第三项研究中,评估了健康青少年(12-17 岁,包括 12-17 岁)单次口服 FDC 后布洛芬和对乙酰氨基酚的生物利用度。
两项成人研究分别招募了 35 名和 46 名受试者,青少年研究招募了 21 名受试者。FDC 中的布洛芬和对乙酰氨基酚与单独或联合使用的单成分具有生物等效性。与空腹相比,食物使 FDC 中布洛芬和对乙酰氨基酚的最大浓度(C)分别降低了 36%和 37%,C 时间(即 t)延迟。在进食和禁食状态下,布洛芬或对乙酰氨基酚的总体药物暴露情况相似。在青少年中,对乙酰氨基酚和布洛芬的总体暴露量与成人相似,对布洛芬的总体暴露量略高。12-14 岁青少年对乙酰氨基酚和布洛芬的暴露量略高于 15-17 岁青少年。所有治疗组的不良事件相似。
当单独或联合使用时,布洛芬/对乙酰氨基酚 250/500mg 的 FDC 的 PK 特征与其单成分成分相似,表明没有药物相互作用和配方影响。与之前对单个成分的研究结果相似,在存在食物的情况下,FDC 中布洛芬和对乙酰氨基酚的吸收速度略有延迟。总体而言,青少年对乙酰氨基酚和布洛芬的暴露量与成人相似,而年龄较小的青少年的暴露量略高于年龄较大的青少年,可能是因为他们的体型较小。FDC 通常具有良好的耐受性。